{"organizations": [], "uuid": "e5ba9f2e0748dc09804b046e4ed34854a641b667", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-anavex-life-sciences-to-initiate-p/brief-anavex-life-sciences-to-initiate-phase-2-study-of-anavex2-73-in-parkinsons-disease-dementia-idUSASC09W35", "country": "US", "domain_rank": 408, "title": "BRIEF-Anavex Life Sciences To Initiate Phase 2 Study Of Anavex®2-73 In Parkinson’S Disease Dementia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.878, "site_type": "news", "published": "2018-04-17T19:14:00.000+03:00", "replies_count": 0, "uuid": "e5ba9f2e0748dc09804b046e4ed34854a641b667"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-anavex-life-sciences-to-initiate-p/brief-anavex-life-sciences-to-initiate-phase-2-study-of-anavex2-73-in-parkinsons-disease-dementia-idUSASC09W35", "ord_in_thread": 0, "title": "BRIEF-Anavex Life Sciences To Initiate Phase 2 Study Of Anavex®2-73 In Parkinson’S Disease Dementia", "locations": [], "entities": {"persons": [{"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "anavex life sciences corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 11:14 AM / Updated 7 minutes ago BRIEF-Anavex Life Sciences To Initiate Phase 2 Study Of Anavex®2-73 In Parkinson’S Disease Dementia Reuters Staff 1 Min Read \nApril 17 (Reuters) - Anavex Life Sciences Corp: \n* ANAVEX LIFE SCIENCES TO INITIATE PHASE 2 STUDY OF ANAVEX®2-73 IN PARKINSON’S DISEASE DEMENTIA AND PROVIDES CLINICAL STUDY UPDATE FOR ANAVEX®2-73 IN RETT SYNDROME \n* ANAVEX LIFE SCIENCES CORP - PLANS TO INITIATE PHASE 2 CLINICAL TRIAL OF ANAVEX 2-73 IN PARKINSON’S DISEASE DEMENTIA (PDD) IN H2 2018 \n* ANAVEX LIFE SCIENCES - ANTICIPATES POTENTIAL INITIATION OF ANAVEX 2-73 PHASE 2 STUDY IN RETT SYNDROME IN H2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T19:14:00.000+03:00", "crawled": "2018-04-17T14:33:58.021+03:00", "highlightTitle": ""}